Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

PHASE3UnknownINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Delayed Graft Function
Interventions
DRUG

ANG-3777

OTHER

Placebo

Trial Locations (30)

10029

Mount Sinai School of Medicine, New York

10032

Columbia University Medical Center, New York

10467

Montefiore Medical Center BRANY, The Bronx

19104

University of Pennsylvania, Philadelphia

20007

Medstar Georgetown University Hospital, Washington D.C.

21201

University of Maryland Medical Center, Baltimore

22904

University of Virginia, Charlottesville

23298

Virginia Commonwealth University (VCU) Medical Center of Virginia, Richmond

27157

Wake Forest Baptist Health, Winston-Salem

33606

Tampa General Hospital, Tampa

40292

University of Louisville, Louisville

43210

Ohio State University Medical Center, Columbus

45221

University of Cincinnati, Cincinnati

48109

University of Michigan Medical Center, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55454

University of Minnesota Medical Center, Minneapolis

60208

Northwestern University, Evanston

60612

Rush University, Chicago

63110

Barnes-Jewish Hospital, St Louis

66045

Kansas University, Lawrence

77030

Houston Methodist Hospital, Houston

80045

University of Colorado Hospital Anschuts Medical Campus, Aurora

85054

Mayo Clinic Hospital in Arizona, Phoenix

90033

Keck Hospital of USC, Los Angeles

90095

UCLA Medical Center, Los Angeles

92123

California Institute of Renal Research, San Diego

94115

California Pacific Medical Center (Sutter), San Francisco

94143

University of California San Francisco Medical Center, San Francisco

95817

UC Davis Medical Center, Sacramento

98195

University of Washinton Medical Center, Seattle

All Listed Sponsors
collaborator

CTI Clinical Trial and Consulting Services

OTHER

lead

Angion Biomedica Corp

INDUSTRY